Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions
Lippencott Williams and Wilkins
MetadataDangos cofnod eitem llawn
Purpose of review: The prevalence of type 2 diabetes globally is reaching epidemic proportions. Type 2 diabetes is strongly associated with increased risk of cardiovascular disease. Atherosclerosis is thought to arise as a result of a chronic inflammatory process within the arterial wall. Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherogenesis, either directly or through associated risk factors. The peroxisome proliferator-activated receptor-γ agonists, the thiazolidinediones, pioglitazone and rosiglitazone, are insulin sensitizing agents, that are licensed for the management of hyperglycaemia. Growing evidence supports an array of additional effects of thiazolidinedione therapy, both immunomodulatory and antiinflammatory, which may attenuate atherogenesis in type 2 diabetes. Recent findings: Studies have shown that thiazolidinedione therapy may lead to risk factor modulation in type 2 diabetes. Thiazolidinediones treatment has been shown to reduce blood pressure, modify the atherogenic lipid profile associated with type 2 diabetes, reduce microalbuminuria and ameliorate the prothrombotic diathesis. Further evidence suggests that thiazolidinediones therapy inhibits the inflammatory processes which may be involved in atherosclerotic plaque initiation, propagation and destabilization. Summary: Modification of insulin resistance by thiazolidinedione therapy in type 2 diabetes and the range of pleiotropic effects may not only impact on incident type 2 diabetes, but also on associated cardiovascular disease. Numerous large clinical endpoint studies are under way to investigate these issues.
Current Opinion in Lipidology
Current Opinion in Lipidology, 14 (6), pp.567-573
Dynodwr Gwrthrych Digidol (DOI)http://dx.doi.org/10.1097/00041433-200312000-00004
Yn dangos eitemau sy’n perthyn drwy deitl, awdur, pwnc a chrynodeb.
O'Morain, Victoria (University of Wales Institute Cardiff, 2012)Thiazolidinediones (TZDs) are a class of oral anti-hyperglycaemic agents receiving continued attention regarding potential implications of TZD therapy on risk of negative cardiovascular outcomes among patients with type 2 ...
An investigation into motility characteristics in THP-1 cells - relevance for type 2 diabetes mellitus Wheat, Richard (Cardiff Metropolitan University, 2011)In recent times, it has become established that common obesity linked Type 2 Diabetes Mellitus (T2DM) is a disease with an underlying chronic systemic inflammatory component, a central feature of which is the infiltration ...
The Effects of CLA (CLA/9:11) on the Expression of RAGE and sRAGE in THP-1 cells in Type 2 Diabetes Harris, Christian (University of Wales Institute Cardiff, 2012)The multi-ligand receptor Receptor for Advanced Glycated End Products, RAGE has been implicated in the pathogenesis of several chronic diseases such as inflammation, atherosclerosis and Diabetes. In Diabetes, hyperglycaemic ...